Search

Amaylia Oehadian,1 Andini Kartikasari,2 Lusi Mersiana,1 Stephanie Victoria Gunadi,3 Gusti Fungani,1 Putri Vidyaniati,1 Dimmy Prasetya,1 Indra Wijaya,1 Pandji Irani Fianza,1 Trinugroho Heri Fadjari,1 Nanny Natalia Sutedjo4 1Division of Hematology and Oncology Medic, Internal Medicine Department, Faculty of Medicine, Padjadjaran University/ Dr. Hasan Sadikin General Hospital, Bandung, Indonesia; 2Bandung City Regional General Hospital, Bandung, Indonesia; 3Internal Medicine Department, Faculty of Medicine, Padjadjaran University/ Dr. Hasan Sadikin General Hospital, Bandung, Indonesia; 4Endocrinology and Metabolism Division, Internal Medicine Department, Faculty of Medicine, Padjadjaran University/ Dr. Hasan Sadikin General Hospital, Bandung, IndonesiaCorrespondence: Amaylia Oehadian, Department of Internal Medicine, Padjadjaran University/ Dr. Hasan Sadikin General Hospital, Jl. Pasteur No. 38, Pasteur, Bandung, West Java, 40161, Indonesia, Email amaylia.oehadian@unpad.ac.idBackground: No specific data have been systematically collected regarding lymphoma patient characteristics, while non-Hodgkin lymphoma (NHL) is identified as the 7th most common cancer and Hodgkin lymphoma (HL) is the 28th. Inflammation plays an important role in the pathogenesis and progression of lymphoma. Malnutrition is an adverse prognostic factor in lymphoma. Systemic Inflammatory Index (SII), Prognostic Nutritional Index (PNI), and Advanced Lung Cancer Inflammation Index (ALI) were biomarkers depicting inflammation and nutritional status. This study aims to describe the clinical and biomarker characteristics of both HL and NHL patients.Methods: This descriptive study used a cross-sectional design, and data were collected from Hasan Sadikin Hospital lymphoma registry from January 2020 to November 2023. Demographic, staging, and histopathological data were extracted. Three biomarkers were evaluated. Survival curves were drawn using Kaplan–Meier curve analysis, and the log rank test was used

Pandji Irani Fianza,1 Anita Rahmawati,1 Indra Wijaya,1 Amaylia Oehadian,1 Dimmy Prasetya,1 Putri Vidyaniati,1 Gusti Fungani Harti,1 Trinugroho Heri Fadjari,1 Ramdan Panigoro2 1Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia; 2Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, IndonesiaCorrespondence: Pandji Irani Fianza, Department of Internal Medicine, Division of Hematology and Medical Oncology, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Pasteur Street No. 38, Bandung, Indonesia, Tel +62-22-203-4954, Email pandji.irani.fianza@unpad.ac.idAbstract: Thalassemia is a chronic disease caused by impaired globin chain synthesis, leading to ineffective erythropoiesis, hemolysis, and chronic anemia. The treatment of patients with thalassemia, including blood transfusion combined with chelation therapy has progressed and improved their survival and prognosis. However, thalassemia-related psychological problems and impaired health-related quality of life (QoL) challenges still exist. Gender is one of the factors that has been suggested, to contribute to the disparities in psychological outcomes. This review article examined the evidence for gender differences in psychological disturbances and QoL in adolescent and adult patients with thalassemia. A non-systematic search of the literature was conducted in PubMed and Google Scholar for English full-text available from 2013 to 2023. We identified 23 studies with a sample size ≥ 100 that examined gender disparities in anxiety, depression, and QoL in adolescent and adult patients with thalassemia (mean prevalence of female = 53.1%; mean age = 28 years). Our review shows that there are gender disparities in psychological distress and QoL in adolescent and adult patients with thalassemia. Statistically significant gender differences we

Uun Sumardi,1,* Bima Valentino,1 Dimmy Prasetya,1 Josephine Debora,1 Adhi Kristianto Sugianli2,* 1Department of Internal Medicine, Hasan Sadikin General Hospital, Faculty of Medicine Universitas Padjadjaran, Bandung, Indonesia; 2Department of Clinical Pathology, Hasan Sadikin General Hospital, Faculty of Medicine Universitas Padjadjaran, Bandung, Indonesia*These authors contributed equally to this workCorrespondence: Adhi Kristianto Sugianli, Department of Clinical Pathology, Hasan Sadikin General Hospital, Faculty of Medicine Universitas Padjadjaran, Jl. Pasteur No. 38, Bandung, West Java, 40161, Indonesia, Tel +62-22-2033307, Email adhi.kristianto@unpad.ac.idPurpose: Coronavirus disease 2019 (COVID-19) is a new respiratory tract infection caused by severe acute respiratory syndrome coronavirus-2. The presence of secondary pulmonary bacterial infection (SPBI) made COVID-19 difficult to treat. Neutrophil-lymphocyte count ratio (NLR) is a systemic inflammatory marker used in the diagnosis and prognosis of viral or bacterial infection. At the first 3– 5 days after hyperinflammation, it occurs in relation to clinical outcome. Therefore, this study aimed to evaluate the diagnostic value of NLR based on leukocyte kinetics upon admission and after 72 hours among COVID-19 patients with or without SPBI.Patients and Methods: This retrospective cross-sectional study analyzed medical records data of admitted patients with COVID-19 according to the International Classification of Disease 10th Revision (ICD-10) between January and December 2021. The list of patients was extracted and followed by a hand search to identify the inclusion or exclusion criteria and stratified into proven and non-proven SPBI based on clinical data. The study distinguished between SPBI by means of a cut-off value (COV) on the first (D1) and third day (D3), assessed using receiver operating characteristics (ROC), as well as determined the magnitude of sensitivity, specificity